Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

34P - Pharmacogenomics of docetaxel response in prostate cancer: A precision medicine initiative

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Abhinav Grover

Citation

Annals of Oncology (2020) 31 (suppl_1): S16-S16. 10.1016/annonc/annonc84

Authors

A. Grover1, S. Greenfield2, S. Kaplan2, R. Stevenson2, E. Uchio2

Author affiliations

  • 1 University of California, Irvine School of Medicine, 92617 - Irvine/US
  • 2 University of California, 92617 - Irvine/US
More

Resources

Abstract 34P

Docetaxel therapy is approved for castration-resistant metastatic prostate cancer. However, it is unknown whether docetaxel should be added to the treatment regimen after patients become resistant to androgen deprivation therapy or only once they develop metastasis. Therefore, the aim of the study was to identify demographic, clinical and genetic predictors of docetaxel response which would help optimize both its use and timing for initiation.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings